Maryangely Moreno Campa, MD
Hematology & Oncology · Caguas, PRNPI 1356659510
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $19,094 of the $27,729 with a category attached, or 68.9%. 41 manufacturers reported payments, led by Merck at 29.5% of the total. 2025 is the largest year on record at $9,967, 6.5 times the $1,543 reported in 2019.
Across 830 payments — averaging $33.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$8K
- AstraZeneca$3K
- E.r. Squibb & Sons, L.L.C.$2K
- Johnson & Johnson$2K
- R-pharm US LLC$1K
- Eli Lilly Export S.A. Puerto Rico Branch$1K
- plus $9K from 35 others
Across 6 payments — averaging $25,294 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$70K
- Pfizer$59K
- E.r. Squibb & Sons, L.L.C.$23K
What the payments were for
- Speaking & faculty fees$1,2004%
- Travel & lodging$6,77024%
- Food & beverage$19,09469%
- Education$6642%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 69 | $8,174 |
| AstraZeneca | 111 | $2,654 |
| E.r. Squibb & Sons, L.L.C. | 111 | $2,485 |
| Johnson & Johnson(2 entities) | 98 | $2,444 |
| R-pharm US LLC | 2 | $1,326 |
| Eli Lilly Export S.A. Puerto Rico Branch | 48 | $1,309 |
| PBG Puerto Rico LLC | 58 | $1,282 |
| AbbVie | 49 | $1,176 |
| Genentech USA, Inc. | 56 | $1,135 |
| Amgen | 38 | $915 |
| Novartis | 25 | $551 |
| Sanofi | 21 | $464 |
| Lilly USA, LLC | 8 | $307 |
| Bayer Puerto Rico Inc. | 14 | $305 |
| Regeneron Healthcare Solutions, Inc. | 11 | $287 |
| Eisai Inc. | 9 | $279 |
| Sanofi-aventis U.S. LLC | 3 | $214 |
| Bayer | 9 | $205 |
| Tempus AI, Inc | 9 | $194 |
| Seagen Inc. | 8 | $183 |
| Incyte Corporation | 8 | $178 |
| GSK | 6 | $168 |
| Rigel Pharmaceuticals, Inc. | 7 | $157 |
| Astellas Pharma US Inc | 7 | $153 |
| Pfizer | 4 | $144 |
| Gilead | 6 | $127 |
| ADC Therapeutics America, Inc. | 1 | $120 |
| Exelixis Inc. | 6 | $119 |
| Pfizer Pharmaceuticals LLC | 2 | $113 |
| Clovis Oncology, Inc. | 5 | $108 |
| Puma Biotechnology, Inc. | 5 | $103 |
| Caris MPI, Inc. | 3 | $72 |
| Beigene USA, Inc. | 3 | $72 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Sobi, Inc | 2 | $42 |
| Taiho Oncology, Inc. | 1 | $25 |
| Verity Pharmaceuticals Inc. | 1 | $21 |
| Genmab U.S., Inc. | 1 | $21 |
| Organon | 1 | $20 |
| Ipsen Biopharmaceuticals, Inc | 1 | $17 |
| Pharmaand GmbH | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$27,729 in reported general payments places this provider in the 85th percentile of 138 hematology & oncology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 45 | $639,310 |
| IbrancePalbociclib | 36 | $584,355 |
| ErleadaApalutamide | 44 | $494,810 |
| RevlimidLenalidomide | 19 | $422,849 |
| ErivedgeVismodegib | 28 | $368,326 |
| TalzennaTalazoparib Tosylate | 11 | $197,639 |
| ImfinziDurvalumab | 13 | $159,478 |
| ProliaDenosumab | 20 | $35,097 |
| Abiraterone Acetate | 20 | $27,898 |
| EliquisApixaban | 14 | $8,383 |
| Exemestane | 60 | $4,323 |
| Anastrozole | 213 | $3,148 |
| Hydroxyurea | 42 | $1,572 |
| Fentanyl | 11 | $1,328 |
| Ondansetron Hcl | 82 | $976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Talzenna, Eliquis | $144 | $790,37761 claims |
| Astellas Pharma US IncXtandi | $153 | $639,31045 claims |
| Johnson & JohnsonErleada | $2,444 | $494,81044 claims |
| Genentech USA, Inc.Erivedge | $1,135 | $368,32628 claims |
| AstraZenecaImfinzi | $2,654 | $159,47813 claims |
| AmgenProlia | $915 | $35,09720 claims |
| AbbVieSynthroid | $1,176 | $88618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 138 hematology & oncology providers in Puerto Rico.
Other hematology & oncology in Caguas
- Carlos Mendez SerranoCaguas$91K
- Maria Garcia PallasCaguas$72K
- Maribel CottoCaguas$22K
- Evelyn Fonseca RiveraCaguas$21K
- Edgardo Rodriguez MongeCaguas$21K
- Alexis Cruz ChaconSan Juan$450K
- Jose Lozada CostasSan Juan$260K
- Cristian Rodriguez ArochoSan Juan$227K
- Noridza Rivera RodriguezSan Juan$177K
- Joel Lopez-FigueroaHumacao$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.